Asbestos Burden Predicts Survival in Pleural Mesothelioma

Christensen, Brock C.; Godleski, John J.; Roelofs, Cora; Longacker, Jennifer L.; Bueno, Raphael; Sugarbaker, David J.; Marsit, Carmen J.; Nelson, Heather H.; Kelsey, Karl T.

doi:10.1289/ehp.11151

Cited by 27 publications

(32 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This was due mainly to residency and not occupational exposure. Pathology in our study was not significant contrary to many studies (Christensen et al, 2008;Ak et al, 2009). The mean survival was 16 and 13 months for the epithelial and mixed versus 5months for the sarcomatous.…”

Section: Discussioncontrasting

confidence: 99%

Survival of Mesothelioma in a Palliative Medical Care Unit in Egypt

Ibrahim

Abou-Elela²,

Darwish³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: This study was to evaluate the survival of patients with pleural and intraperitoneal malignant mesothelioma and to investigate the efficacy of chemotherapy (CT) as well as radiotherapy (RTH) and surgery compared to best supportive care (BSC). Materials and Methods: Forty patients with malignant mesothelioma (38 with pleural and 2 with intraperitoneal) were enrolled. Twenty seven patients underwent (CT) chemotherapy of which 2 also received (RTH) and surgery was only for biopsy in 15/40. Combination chemotherapy included cisplatin-gemcitabine, cisplatin-navelbine and cisplatin (or carboplatin) with premetrexed. Thirteen patients received only best supportive care. Results: A total of 12 (30%) patients were male, and 28 (70%) female. Median age was 54.0 years and the male/female ratio was 1/2.33 (P=0.210). Residential exposure played a major role in two regions, Helwan and Shoubra, in 20% and 15%, respectively. Overall mean survival time was 13.9±2.29 months. That for patients who had received best supportive care was 7.57±1.85 months, for chemotherapy was 16.5±3.20 months, and multimodality treatment regimen 27±21.0 months (P=0.028). Kaplan-Meier survival did not significantly vary for sex, residence and the pathological types epithelial, mixed and sarcomatous. The median survival for performance status and treatment modalities was significant (P=0.001 and 0.028). Best supportive care using opioids with a mean dose of 147.1 mg (range 0-1680) of morphine sulphate produced good subjective response and reasonable quality of life but did not affect survival. Conclusions: We conclude that CT prolongs survival compared to BSC in patients with malignant mesothelioma. Moreover, using escalating doses of opioids provides good pain relief and subjective responses.

show abstract

Section: Discussioncontrasting

confidence: 99%

Survival of Mesothelioma in a Palliative Medical Care Unit in Egypt

Ibrahim

Abou-Elela²,

Darwish³

2013

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Recent studies have correlated asbestos exposure with shorter survival in patients with MM (Flores et al, 2007;Christensen et al, 2008), which could suggest differences in differential gene and miRNA signatures between asbestos exposed versus nonexposed patients with MM. However, the analysis made in this study did not reveal any significant differences in miRNA expression between asbestos exposed and nonexposed patients (Fig.…”

Section: Discussionmentioning

confidence: 99%

CDKN2A, NF2, and JUN are dysregulated among other genes by miRNAs in malignant mesothelioma—A miRNA microarray analysis

Guled

Lahti

Lindholm

et al. 2009

Genes Chromosomes & Cancer

251

185

View full text Add to dashboard Cite

Malignant mesothelioma (MM) is an aggressive cancer arising from mesothelial cells, mainly due to former asbestos exposure. Little is known about the microRNA (miRNA) expression of MM. miRNAs are small noncoding RNAs, which play an essential role in the regulation of gene expression. This study was carried out to analyze the miRNA expression profile of 17 MM samples using miRNA microarray. The analysis distinguished the overall miRNA expression profiles of tumor tissue and normal mesothelium. Differentially expressed miRNAs were found in tumor samples compared with normal sample. Twelve of them, let-7b*, miR-1228*, miR-195*, miR-30b*, miR-32*, miR-345, miR-483-3p, miR-584, miR-595, miR-615-3p, and miR-885-3p, were highly expressed whereas the remaining nine, let-7e*, miR-144*, miR-203, miR-340*, miR-34a*, miR-423, miR-582, miR-7-1*, and miR-9, were unexpressed or had severely reduced expression levels. Target genes for these miRNAs include the most frequently affected genes in MM such as CDKN2A, NF2, JUN, HGF, and PDGFA. Many of the miRNAs were located in chromosomal areas known to be deleted or gained in MM such as 8q24, 1p36, and 14q32. Furthermore, we could identify specific miRNAs for each histopathological subtype of MM. Regarding risk factors such as smoking status and asbestos exposure, significantly differentially expressed miRNAs were identified in smokers versus nonsmokers (miR-379, miR-301a, miR-299-3p, miR-455-3p, and miR-127-3p), but not in asbestos-exposed patients versus nonexposed ones. This could be related to the method of assessment of asbestos exposure as asbestos remains to be the main contributor to the development of MM.

show abstract

“…A clear relationship between chronic inflammation (due to asbestos and asbestos-like fibers) and MPM development is supported by both epidemiological observations and in vitro/in vivo models of the disease. 34,37,55,56 Furthermore, the widespread use of asbestos (and asbestos-like material) in the 70s allows epidemiologists to expect a peak of the disease within the next 15 years. 57,58 Therefore, there is a great need for novel therapeutic approaches for MPM.…”

Section: Butein Affects the Resistance Of Mpm Cells To Pemetrexedmentioning

confidence: 99%